Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · IEX Real-Time Price · USD
0.393
+0.005 (1.19%)
At close: Apr 26, 2024, 3:57 PM
0.389
-0.003 (-0.87%)
After-hours: Apr 26, 2024, 4:00 PM EDT
Galmed Pharmaceuticals Stock Forecast
GLMD's stock price has decreased by -91.42% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for GLMD stock has a target of 4.00, which predicts an increase of 918.59% from the current stock price of 0.39.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 24, 2023.
Analyst Ratings
According to 1 stock analyst, the rating for GLMD is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $4 | Hold → Strong Buy | Upgrades | $4 | +918.59% | Jul 24, 2023 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 8, 2022 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $75 → $15 | Strong Buy → Hold | Downgrades | $75 → $15 | +3,719.71% | Aug 8, 2022 |
| Raymond James | Raymond James | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 18, 2022 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 3, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.32
from -2.50
EPS Next Year
-1.05
from -1.32
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | n/a | n/a |
| Avg | n/a | n/a | n/a | n/a | n/a |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -1.35 | -1.08 | -1.06 | -1.93 |
| Avg | -1.32 | -1.05 | -1.03 | -1.88 |
| Low | -1.26 | -1.01 | -0.99 | -1.80 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.